XML 63 R51.htm IDEA: XBRL DOCUMENT v3.25.3
Segments - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
3 Months Ended 9 Months Ended
May 21, 2024
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting Information [Line Items]                  
Stock-based compensation expense $ 600,000 $ 1,456,080     $ 1,640,116     $ 4,673,290 $ 4,776,623
Depreciation and amortization   78,841     88,949     248,628 269,691
Net loss   (14,964,875) $ (14,433,881) $ (15,046,132) (14,597,366) $ (14,079,927) $ (14,307,829) (44,444,888) (42,985,123)
Reportable Segment                  
Segment Reporting Information [Line Items]                  
Non-program expenses   1,894,410     1,380,336     4,677,209 4,223,505
Employee-related costs   4,892,610     5,195,836     15,216,089 16,126,828
Stock-based compensation expense   1,456,080     1,640,116     4,673,290 4,776,623
Depreciation and amortization   78,841     88,949     248,628 269,691
Other segment items   (415,832)     (676,382)     (1,178,362) (2,528,123)
Net loss   14,964,875     14,597,366     44,444,888 42,985,123
Reportable Segment | atebimetinib (IMM-1-104)                  
Segment Reporting Information [Line Items]                  
Program expenses   5,091,491     4,591,547     14,518,757 12,045,176
Reportable Segment | IMM-6-415                  
Segment Reporting Information [Line Items]                  
Program expenses   292,917     1,212,407     2,195,284 3,372,353
Reportable Segment | Other programs                  
Segment Reporting Information [Line Items]                  
Program expenses   $ 1,674,358     $ 1,164,557     $ 4,093,993 $ 4,699,070